ABCL vs TGT · rev $12.4M vs P/E 17, rev $51.98B
Abcellera Biologics Inc (ABCL) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
ABCL currently screens at market cap $1.12B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the ABCL and TGT stock pages for the full models.
Not investment advice.